Human CAR-T Cells engineered using the Solupore Ex Vivo Cell Engineering Platform are highly cytotoxic and specific against CD19+ cells in vitro

Non-viral siRNA delivery to T cells: Challenges and opportunities in cancer immunotherapy

“…As membrane-permeabilization based technologies offer direct access of siRNA to the cytosol and do not depend on endocytosis/endosomal escape, they can achieve high delivery efficiencies in hard-to-transfect cell types compared to carrier-based delivery methods [28]. On the other hand, creating sufficiently large pores to achieve sufficiently high cargo delivery while avoiding long-lasting membrane damage that could influence cell viability and/or functionality remains an intricate balance [69][70][71]. Furthermore, sufficient throughput and scalability can be important concerns for the clinical translation of some approaches (e.g.…”

“…siRNA, mRNA, pDNA, proteins) have been delivered in distinct cell types, including primary cells [164]. Furthermore, Avectas very recently claimed the successful engineering of human CAR T cells (60% delivery efficiency) via Solupore TMmediated delivery of CD19 mRNA [71]. Here, investigating the expression of more than 550 immune-regulated genes, a minimal impact of the Solupore TM delivery platform on T cell functionality is reported.…”

Non-viral transfection technologies for next-generation therapeutic T cell engineering

“…Shortly after this initial proof-ofconcept study, Avectas indicated that efficacious mRNA transfection of primary human T cells with 30-40% efficiency could be obtained, with minimal perturbation of cell viability and retention of their proliferative potential (O'Dea et al, 2017b). Recent work has also indicated that the Solupore technology could be used to engineer T cells with CD19 CAR mRNA, reporting average CD19 CAR transfection efficiencies of 60% (viability not mentioned) and effective killing of cancer cells in vitro (Kavanagh et al, 2020). In view of clinical-grade T cell manufacturing, Avectas is developing a GMP-compliant closed continuous system for scalable and high-throughput T cell engineering (Aijaz et al, 2018).…”